EGFR and neoplasm: Anti-EGFR-Ab acquired resistance (AR) almost invariably occurs in pts who initially benefit, and this has predominantly been studied retrospectively in circulating tumor DNA (ctDNA) (Bettegowda et al., 2014, Diaz et al., 2012, Misale et al., 2012).